Alliance A031704- Pd-Inhibitor (Nivolumab) And Ipilimumab Followed By Nivolumab Vs. Vegf Tki Cabozantinib With Nivolumab: A Phase III Trial In Metastatic Untreated Renal Cell Cancer [Pdigree]
Posted Date: May 22, 2020
- Investigator: Robert Franklin
- Specialties: Cancer, Oncology
- Type of Study: Drug
The goal of the study is to compare the overall survival (OS) in patients with metastatic RCC treated with ipilimumab- nivolumab followed by either nivolumab versus cabozantinib-nivolumab
Criteria:
To Be Eligible: Must Have Renal Cell Carcinoma, Measurable Disease, Karnofsky Performance Status <70%, No Prior Systemic Therapy For Renal Cell Cancer, No Severe Hypersensitivity To Study Drugs, No Active Infection Or Disease That Could Impact Study Treatment
Keywords:
Kidney Cancer, Renal Cell
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com